Philip B. Gorelick
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Philip B. Gorelick has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Yvonne Harris
2 shared publicationsCheryl Easley
1 shared publicationDavid C Garron
1 shared publication- David L. Nyenhuis
Chicago Medical Center, University of Illinois
1 shared publication DeJuran Richardson
1 shared publicationDejuran Richardson
1 shared publication
Latest Publications
- Open Access
- 1 May 2004
- Published by Wiley in Clinical Cardiology
- Vol. 27 (5) , 4-11
Epidemiology of transient ischemic attack and ischemic stroke in patients with underlying cardiovascular disease
- 1 May 2004
- Published by Wiley in Clinical Cardiology
- Vol. 27 (5) , 4-11
Open AccessEpidemiology of transient ischemic attack and ischemic stroke in patients with underlying cardiovascular disease
- Open Access
- 11 June 2003
- Published by American Medical Association (AMA) in JAMA
- Vol. 289 (22) , 2947-2957
Aspirin and Ticlopidine for Prevention of Recurrent Stroke in Black PatientsA Randomized Trial
Blacks are disproportionately affected by stroke, yet they have been underrepresented in clinical trials.1-8 Recommendations for stroke prevention in this population have been based largely on trials that have included few black participants. This may not be an optimal practice because blacks are among those with a higher prevalence of major cardiovascular risk factors, a different distribution of atherosclerotic occlusive cerebral vascular lesions, vascular biological differences such as low renin hypertension, and a different pattern of use of medical procedures and access to care8-13 that could influence outcome.
- 11 June 2003
- Published by American Medical Association (AMA) in JAMA
- Vol. 289 (22) , 2947-2957
Open AccessAspirin and Ticlopidine for Prevention of Recurrent Stroke in Black PatientsA Randomized Trial
Blacks are disproportionately affected by stroke, yet they have been underrepresented in clinical trials.1-8 Recommendations for stroke prevention in this population have been based largely on trials that have included few black participants. This may not be an optimal practice because blacks are among those with a higher prevalence of major cardiovascular risk factors, a different distribution of atherosclerotic occlusive cerebral vascular lesions, vascular biological differences such as low renin hypertension, and a different pattern of use of medical procedures and access to care8-13 that could influence outcome.
- 1 January 2003
- Vol. 13 (2) , 208-12
The Black Seventh-Day Adventist exploratory health study.
African Americans are at high risk for stroke and dementia. Modifications of lifestyle, however, might lower this risk. The Seventh-Day Adventist (SDA) Church encourages both spiritual adherence and a healthy lifestyle. Members are encouraged to exercise and are discouraged from smoking, drinking alcoholic or caffeinated beverages, or eating meat. The present study describes an exploratory project in 2 Black SDA congregations (N = 82) designed to characterize the lifestyle, dietary, and spiritual health habits of these congregations, and to test the feasibility of collecting such information in the Black SDA community at large. Three separate data collection methods are described and evaluated. Data demonstrate that the sample differs significantly from the African-American community at large in dietary, lifestyle, and spiritual health habits. The Black SDA community represents a unique opportunity to test the effects of diet, lifestyle, and spirituality on risk for stroke and dementia.
- 1 January 2003
- Vol. 13 (2) , 208-12
The Black Seventh-Day Adventist exploratory health study.
African Americans are at high risk for stroke and dementia. Modifications of lifestyle, however, might lower this risk. The Seventh-Day Adventist (SDA) Church encourages both spiritual adherence and a healthy lifestyle. Members are encouraged to exercise and are discouraged from smoking, drinking alcoholic or caffeinated beverages, or eating meat. The present study describes an exploratory project in 2 Black SDA congregations (N = 82) designed to characterize the lifestyle, dietary, and spiritual health habits of these congregations, and to test the feasibility of collecting such information in the Black SDA community at large. Three separate data collection methods are described and evaluated. Data demonstrate that the sample differs significantly from the African-American community at large in dietary, lifestyle, and spiritual health habits. The Black SDA community represents a unique opportunity to test the effects of diet, lifestyle, and spirituality on risk for stroke and dementia.
- 1 July 2002
- Published by Elsevier in The Lancet Neurology
- Vol. 1 (3) , 149-156
New horizons for stroke prevention: PROGRESS and HOPE
- 1 July 2002
- Published by Elsevier in The Lancet Neurology
- Vol. 1 (3) , 149-156
New horizons for stroke prevention: PROGRESS and HOPE
- 1 March 2002
- Published by Wolters Kluwer Health in Stroke
- Vol. 33 (3) , 862-875
Stroke Prevention Therapy Beyond Antithrombotics: Unifying Mechanisms in Ischemic Stroke Pathogenesis and Implications for Therapy
Background — It is estimated that about half of cardiovascular disease risk is explained by conventional risk factors. The realization that atherosclerosis is an inflammatory disease has led to a search for new stroke and cardiovascular disease risk factors and treatments. As such, the vulnerable atherosclerotic plaque has become the main focus for new medical strategies for plaque stabilization and stroke prevention. Summary of Review — In this invited review, I discuss inflammation as a possible risk factor for stroke, unifying mechanisms in ischemic stroke pathogenesis, and new avenues for stroke prevention—statin agents, angiotensin-converting enzyme inhibitors, and vitamins. These new stroke prevention therapies may help to reduce inflammation, serve to stabilize the atherosclerotic plaque, or act by other protective mechanisms. Conclusion — Beyond the traditional antithrombotic agents, statin agents, angiotensin-converting enzyme inhibitors, and vitamins may prove to be important additions to our armamentarium for stroke prevention.
- 1 March 2002
- Published by Wolters Kluwer Health in Stroke
- Vol. 33 (3) , 862-875
Stroke Prevention Therapy Beyond Antithrombotics: Unifying Mechanisms in Ischemic Stroke Pathogenesis and Implications for Therapy
Background — It is estimated that about half of cardiovascular disease risk is explained by conventional risk factors. The realization that atherosclerosis is an inflammatory disease has led to a search for new stroke and cardiovascular disease risk factors and treatments. As such, the vulnerable atherosclerotic plaque has become the main focus for new medical strategies for plaque stabilization and stroke prevention. Summary of Review — In this invited review, I discuss inflammation as a possible risk factor for stroke, unifying mechanisms in ischemic stroke pathogenesis, and new avenues for stroke prevention—statin agents, angiotensin-converting enzyme inhibitors, and vitamins. These new stroke prevention therapies may help to reduce inflammation, serve to stabilize the atherosclerotic plaque, or act by other protective mechanisms. Conclusion — Beyond the traditional antithrombotic agents, statin agents, angiotensin-converting enzyme inhibitors, and vitamins may prove to be important additions to our armamentarium for stroke prevention.